A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors (Q46483294)
Jump to navigation
Jump to search
scientific article published in July 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors |
scientific article published in July 2014 |
Statements
1 reference
A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors (English)
1 reference
Mark C Genovese
1 reference
Maria Greenwald
1 reference
Chul-Soo Cho
1 reference
Alberto Berman
1 reference
Ling Jin
1 reference
Gregory S Cameron
1 reference
Olivier Benichou
1 reference
Li Xie
1 reference
Daniel Braun
1 reference
Pierre-Yves Berclaz
1 reference
Subhashis Banerjee
1 reference
1 July 2014
1 reference
66
1 reference
7
1 reference
1693-1704
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference